Form 4: Imunon Director Acquires Stock Options

Christine Pellizzari, a director of Imunon, Inc., acquired stock options exercisable for 3,750 shares of common stock at a price of $0.8651 on March 14, 2025.

Summary

• On March 14, 2025, Christine Pellizzari, a director of Imunon, Inc., was granted stock options to purchase 3,750 shares of Imunon's common stock.
• The exercise price of these options is $0.8651 per share.
• The options vest in three tranches: 1/2 on the grant date, 1/4 on the one-year anniversary, and 1/4 on the two-year anniversary of the grant date.
• The options expire on March 14, 2035.
• Susan Eylward, acting as Attorney-in-Fact for Christine Pellizzari, signed the Form 4 filing on March 18, 2025.

Sentiment

Score: 6

Explanation: The document is a neutral regulatory filing. The grant of options could be seen as mildly positive, indicating confidence, but it's a routine event.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

There are no specific forward-looking statements in this document.

Industry Context

This is a standard regulatory filing related to insider transactions. It's common for directors and officers of publicly traded companies to receive stock options as part of their compensation packages.

Comparison to Industry Standards

• Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders.
• Vesting schedules, such as the one described (1/2 on grant date, 1/4 on the one-year anniversary, and 1/4 on the two-year anniversary), are typical in the industry to incentivize long-term commitment.
• Companies like Amgen, Gilead Sciences, and Biogen also utilize stock options as part of their executive compensation packages.

Stakeholder Impact

• The grant of stock options to a director could have a minor positive impact on shareholder sentiment.

Key Dates